Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects

PHARMACOGENOMICS JOURNAL · Published 2026-08-01 · DOI 10.1038/s41397-026-00424-2

Free full text

Authors (50)

Chris Eijsbouts, Yunxuan Jiang, James R. Ashenhurst, Julie M. Granka, 23andMe Research Team, Stella Aslibekyan, Robert K. Bell, Zayn Cochinwala, Sayantan Das, Kahsaia de Brito, Emily DelloRusso, Devika Dhamija, Payam Dibaeinia, Sarah L. Elson, Nicholas Eriksson, Shirin Fuller, Chris German, Larry Hengl, Barry Hicks, David A. Hinds, Michael V. Holmes, M. Reza Jabalameli, Ethan M. Jewett, Matt Kmiecik, Katelyn Kukar Bond, Alan Kwong, Keng-Han Lin, Yanyu Liang, Aly Khan, Matthew H. McIntyre, Alex Moran, Carrie Northover, Jared O’Connell, Steve Pitts, Shubham Saini, Anjali J. Shastri, Jingchunzi Shi, Suyash Shringarpure, Teague Sterling, Qiaojuan Jane Su, Joyce Y. Tung, Vinh Tran, Xin Wang, Catherine H. Weldon, Wanwan Xu, Steven Pitts, Adam Auton, Noura S. Abul-Husn, Alison Chubb, R. Ryanne Wu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Eijsbouts, C., Jiang, Y., Ashenhurst, J., et al. (2026). Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects. PHARMACOGENOMICS JOURNAL. https://doi.org/10.1038/s41397-026-00424-2

Related articles

• Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• A functional ancestry-linked regulatory haplotype influences CYP2D6 expression · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation · PHARMACOGENOMICS JOURNAL · 2026 · Same journal
• Genetic markers of early response to lurasidone in acute schizophrenia · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• Meta-analysis and review of in silico methods in drug discovery – part 1: technological evolution and trends from big data to chemical space · PHARMACOGENOMICS JOURNAL · 2025 · Same journal
• The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke · PHARMACOGENOMICS JOURNAL · 2026 · Same journal